History: The EORTC 24971/TAX 323 a phase III study of 358 individuals with unresectable locoregionally advanced squamous cell carcinoma of the head and neck showed an improved progression-free and overall HDAC-42 survival (OS) with less toxicity when docetaxel (T) was added to cisplatin and 5-fluorouracil (PF) for induction and given before radiotherapy (RT). to HRQOL assessments was 97% at baseline but fallen to 54% by 6 months. Data were analysed up to 6 months. There was a pattern towards improved global HRQOL during the treatment period. At 6 months after the end of RT global HRQOL was higher in the TPF arm than in the PF arm but the low compliance does not allow to attract definitive conclusions. Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2 but to a limited extent. Summary: Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity weighed against PF but also appears to improve global HRQOL in HDAC-42 a far more sustainable way. (2007). The trial accepted by the EORTC process review committee as well as the ethics committee of every participating center was conducted relative to the Helsinki Declaration. All individuals provided written educated consent before randomisation. Randomisation was carried out centrally in the EORTC headquarters Belgium using a minimisation technique. Randomisation was balanced according to the main tumour site (oral cavity oropharynx hypopharynx or larynx) and the centre. Methods for QOL data collection The EORTC QOL Questionnaire C30 (EORTC QLQ-C30 version 3) was selected as it is definitely a powerful validated tool and the one that is definitely most frequently used in randomised medical trials (Aaronson pain thermometer was also used. As per protocol the HRQOL questionnaires had to be completed before knowledge of treatment allocation by the patient (up to 2 weeks before randomisation) at cycle 2 just before the next cycle (at the time of tumour assessment) at the end of CT before starting RT (at the time of tumour assessment) and then 6 and 9 weeks after completion of RT. Individuals were asked to total the questionnaires no matter stable or progressive disease or relapse. Recommendations for administering questionnaires were provided ensuring standardisation of HRQOL data by HDAC-42 all staff (Young pain thermometer data confirmed that there was Hdac8 no difference in pain intensity between the two treatment arms (data not demonstrated). Evaluation of the clinician-assessed PSS-HN tool showed high compliance (75% at 6 months after RT) as these data were collected from case-report forms rather than HRQOL questionnaires. This tool provides the clinician’s rating of performance status; an outcome related to however not equivalent to QOL. Changes from baseline were analysed for the three items of this tool that is RT only performed better in the combined arm (Bonner et al 2006 Curran et al 2007 and although there was a gain in OS no variations in HRQOL were observed. This study is the 1st reporting HRQOL during induction CT followed by RT showing an improvement during the 1st weeks after start of neo-adjuvant CT. However we did not measure the QoL during or in the last week of the RT. Therefore we can only speculate within the QoL during the RT in the TPF and PF arm. On the one hand it could have been better in the TPF arm because the tendency in a better QoL which was seen after the CT before the start of Rt continued to improve or on the other hand it could have been worse in the TPF arm because docetaxel can act as HDAC-42 a radiosensitiser (Nabell and Spencer 2003 Swallowing dysfunction and aspiration are seen in a high proportion of individuals with SCCHN after combined chemoradiation (Bentzen and Trotti 2007 Consequently swallowing and coughing although not always related to aspiration were selected as main domains for this analysis. A tendency to a higher reduction in swallowing and coughing problems was observed in the TPF arm weighed against the PF arm however the extent from the decrease was limited. Furthermore much less loss of urge HDAC-42 for food was seen in the TPF arm whereas much less weight reduction and more excess weight gain had been seen in the TPF arm by the end of routine 4. Eating complications may derive from both the principal located area of the mind and neck cancer tumor and treatment-induced undesireable effects such as discomfort in the mouth area issues with dentition reduced saliva and complications swallowing. Hence fat loss is normally reported to have an effect on 35-50% of sufferers with SCCHN and may.